CStone Pharmaceuticals Showcases Promising Lymphoma Therapy

CStone Pharmaceuticals (HK:2616) has released an update.

CStone Pharmaceuticals has unveiled promising clinical data for its anti-ROR1 ADC, CS5001, at the 66th ASH Annual Meeting. The data shows significant anti-tumor activity in both Hodgkin and non-Hodgkin lymphomas, with a notable objective response rate of 76.9% in advanced B-cell lymphoma at a specific dose. As the company progresses with global Phase I trials, CS5001 shows potential for market competitiveness as a novel therapy for lymphoma.

For further insights into HK:2616 stock, check out TipRanks’ Stock Analysis page.